The present disclosure relates to the use of the (-) enantiomer of perhexiline (2-(2,2-dicyclohexylethyl)piperidine) for preventing and/or treating a disease, condition or state associated with altered tissue energetics, such as altered myocardial metabolism associated with cardiovascular related disease states. Certain example embodiments of the present disclosure provide a method for preventing and/or treating a disease, condition or state associated with altered tissue energetics in a subject...

A method for treating or preventing a disease, condition or state in a subject in need thereof by administering to the subject an effective amount of the (-)-enantiomer of perhexyline or a pharmaceutically acceptable salt, prodrug or derivative thereof, substantially free of the (+)-enantiomer, or pharmaceutical composition containing same. The disease, condition or state may be associated with altered tissue energetics, impaired tissue energetics, altered cardiac tissue energetics, impaired car...

A method for treating or preventing a disease condition or state in a subject in need thereof by administering to the subject an effective amount of the (-)-enantiomer of perhexyline or a pharmaceutically acceptable salt prodrug or derivative thereof substantially free of the (+)-enantiomer or pharmaceutical composition containing same. The disease condition or state may be associated with altered tissue energetics impaired tissue energetics altered cardiac tissue energetics impaired cardiac tis...

Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an is...

Disclosed are methods for the treatment of chronic heart failure comprising administering to an animal in need thereof an effective amount of perhexiline or a pharmaceutically acceptable salt thereof to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischae...

Disclosed are methods for the treatment of chronic heart failure comprising administering to an animal in need thereof an effective amount of perhexiline or a pharmaceutically acceptable salt thereof to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischae...

Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an is...

The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure, as well as to a method for treating heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said heart failure. The invention further relates to a treatment programme for treating heart failure, which involves the co-use or co-administration of perhexiline with ...

The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure, as well as to a method for treating heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said heart failure. The invention further relates to a treatment programme for treating heart failure, which involves the co-use or co-administration of perhexiline with ...

Disclosed are methods for the treatment of chronic heart failure comprising administering to an animal in need thereof an effective amount of perhexiline or a pharmaceutically acceptable salt thereof to treat said chronic heart failure. The chronic heart failure may be non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischa...